Summary
112.04 -1.13(-1.00%)05/14/2024
Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals plc (JAZZ)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 1.26 | 0.42 | -3.33 | -9.51 | -16.81 | -19.82 | -13.56 | 527.19 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 111.20 | |
| Open | 109.50 | |
| High | 111.56 | |
| Low | 108.60 | |
| Volume | 670,857 | |
| Change | 1.38 | |
| Change % | 1.26 | |
| Avg Volume (20 Days) | 523,104 | |
| Volume/Avg Volume (20 Days) Ratio | 1.28 | |
| 52 Week Range | 103.01 - 146.70 | |
| Price vs 52 Week High | -24.20% | |
| Price vs 52 Week Low | 7.95% | |
| Range | 1.55 | |
| Gap Up/Down | -1.76 | |
Fundamentals | ||
| Market Capitalization (Mln) | 7,061 | |
| EBIDTA | 1,373,081,984 | |
| PE Ratio | 22.6977 | |
| PEG Ratio | 0.8357 | |
| WallStreet Target Price | 181.24 | |
| Book Value | 58.6480 | |
| Earnings Per Share | 4.8300 | |
| EPS Estimate Current Quarter | 4.1800 | |
| EPS Estimate Next Quarter | 4.7000 | |
| EPS Estimate Current Year | 18.5400 | |
| EPS Estimate Next Year | 20.7500 | |
| Diluted EPS (TTM) | 4.8300 | |
| Revenues | ||
| Profit Marging | 0.0861 | |
| Operating Marging (TTM) | 0.1166 | |
| Return on asset (TTM) | 0.0407 | |
| Return on equity (TTM) | 0.0941 | |
| Revenue TTM | 3,843,375,104 | |
| Revenue per share TTM | 60.9560 | |
| Quarterly Revenue Growth (YOY) | 0.0100 | |
| Quarterly Earnings Growth (YOY) | 1.7570 | |
| Gross Profit (TTM) | 3,392,249,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 22.6977 | |
| Forward PE | 5.9347 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.8445 | |
| Revenue Enterprise Value | 2.8841 | |
| EBITDA Enterprise Value | 9.0193 | |
| Shares | ||
| Shares Outstanding | 63,039,600 | |
| Shares Float | 61,252,445 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.08 | |
| Insider (%) | 2.78 | |
| Institutions (%) | 97.15 | |
05/09 09:19 EST - InvestorPlace
7 Cannabis Stocks to Buy for a Smoking-Hot 2024
Among the emerging industries that have captured the attention of investors is the cannabis sector. The cannabis industry has experienced remarkable growth, giving rise to a new breed of top cannabis stocks to buy for investments in May.
7 Cannabis Stocks to Buy for a Smoking-Hot 2024
Among the emerging industries that have captured the attention of investors is the cannabis sector. The cannabis industry has experienced remarkable growth, giving rise to a new breed of top cannabis stocks to buy for investments in May.
05/06 10:31 EST - Zacks Investment Research
Jazz (JAZZ) International Revenue Performance Explored
Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Jazz (JAZZ) International Revenue Performance Explored
Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
05/02 12:31 EST - Zacks Investment Research
Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates
Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.
Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates
Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.
05/01 20:01 EST - Zacks Investment Research
Jazz (JAZZ) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Jazz (JAZZ) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
04/24 11:08 EST - Zacks Investment Research
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
04/24 07:25 EST - Finbold
Three no-brainer stocks to buy with $100
The stock market's strong performance in 2024 has made many investment options too expensive for some traders. However, with the recent pullback, an opportunity has emerged to invest in excellent value picks with $100.
Three no-brainer stocks to buy with $100
The stock market's strong performance in 2024 has made many investment options too expensive for some traders. However, with the recent pullback, an opportunity has emerged to invest in excellent value picks with $100.
04/24 05:21 EST - The Motley Fool
3 No-Brainer Stocks to Buy With $300 Right Now
Dips in the broader market have historically served as a buying opportunity for long-term-minded investors. A majority of online brokers have shelved commission fees and minimum deposit requirements in recent years.
3 No-Brainer Stocks to Buy With $300 Right Now
Dips in the broader market have historically served as a buying opportunity for long-term-minded investors. A majority of online brokers have shelved commission fees and minimum deposit requirements in recent years.
04/15 04:31 EST - Seeking Alpha
Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off
Jazz Pharmaceuticals is rated as a "Buy" due to its current financial health, multiple near-term catalysts, and projected growth for 2024 and 2025. The company's successful commercial products include Xywav, Epidiolex, and Rylaze, which have shown increasing adoption and sales revenues. JAZZ is targeting low-hanging fruit in oncology with its drug Zanidatamab, which has the potential to become a blockbuster drug with up to $2 billion/year in net sales.
Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off
Jazz Pharmaceuticals is rated as a "Buy" due to its current financial health, multiple near-term catalysts, and projected growth for 2024 and 2025. The company's successful commercial products include Xywav, Epidiolex, and Rylaze, which have shown increasing adoption and sales revenues. JAZZ is targeting low-hanging fruit in oncology with its drug Zanidatamab, which has the potential to become a blockbuster drug with up to $2 billion/year in net sales.
03/29 12:37 EST - Zacks Investment Research
Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
03/13 14:25 EST - InvestorPlace
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as innovative of sector as “regular” tech but it just hasn't received the same fervor.
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as innovative of sector as “regular” tech but it just hasn't received the same fervor.
02/29 11:46 EST - Zacks Investment Research
Jazz (JAZZ) Q3 Earnings Lag, Revenues in Line With Estimates
Jazz's (JAZZ) fourth-quarter earnings miss estimates while sales meet the mark. Shares drop 1.5% post the announcement.
Jazz (JAZZ) Q3 Earnings Lag, Revenues in Line With Estimates
Jazz's (JAZZ) fourth-quarter earnings miss estimates while sales meet the mark. Shares drop 1.5% post the announcement.
02/28 20:51 EST - Seeking Alpha
Jazz Pharmaceuticals PLC (JAZZ) Q4 2023 Earnings Call Transcript
Jazz Pharmaceuticals PLC (JAZZ) Q4 2023 Earnings Call Transcript
Jazz Pharmaceuticals PLC (JAZZ) Q4 2023 Earnings Call Transcript
Jazz Pharmaceuticals PLC (JAZZ) Q4 2023 Earnings Call Transcript
02/28 19:31 EST - Zacks Investment Research
Here's What Key Metrics Tell Us About Jazz (JAZZ) Q4 Earnings
The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Here's What Key Metrics Tell Us About Jazz (JAZZ) Q4 Earnings
The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
02/28 18:20 EST - Zacks Investment Research
Jazz Pharmaceuticals (JAZZ) Q4 Earnings Lag Estimates
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $5.02 per share, missing the Zacks Consensus Estimate of $5.26 per share. This compares to loss of $0.07 per share a year ago.
Jazz Pharmaceuticals (JAZZ) Q4 Earnings Lag Estimates
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $5.02 per share, missing the Zacks Consensus Estimate of $5.26 per share. This compares to loss of $0.07 per share a year ago.
02/26 15:20 EST - InvestorPlace
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.
02/23 10:21 EST - Zacks Investment Research
Exploring Analyst Estimates for Jazz (JAZZ) Q4 Earnings, Beyond Revenue and EPS
Besides Wall Street's top -and-bottom-line estimates for Jazz (JAZZ), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Exploring Analyst Estimates for Jazz (JAZZ) Q4 Earnings, Beyond Revenue and EPS
Besides Wall Street's top -and-bottom-line estimates for Jazz (JAZZ), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
02/20 17:00 EST - InvestorPlace
3 Cannabis Stocks That Could Be Multibaggers in the Making: February Edition
While many top cannabis stocks have existed for years, the U.S. market has warmed up to the cannabinoid sector only recently. About 40 states allow the use of cannabis, although not all permit its recreational administration.
3 Cannabis Stocks That Could Be Multibaggers in the Making: February Edition
While many top cannabis stocks have existed for years, the U.S. market has warmed up to the cannabinoid sector only recently. About 40 states allow the use of cannabis, although not all permit its recreational administration.
02/14 16:15 EST - PRNewsWire
Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024
DUBLIN , Feb. 14, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 full year and fourth quarter financial results on Wednesday, February 28, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m.
Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024
DUBLIN , Feb. 14, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 full year and fourth quarter financial results on Wednesday, February 28, 2024, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m.
02/08 11:31 EST - Zacks Investment Research
JAZZ Boosts Oncology Pipeline With KRAS Inhibitor Program
JAZZ inks a deal to acquire global rights to Redx Pharma's KRAS inhibitor program to strengthen its early-stage oncology pipeline.
JAZZ Boosts Oncology Pipeline With KRAS Inhibitor Program
JAZZ inks a deal to acquire global rights to Redx Pharma's KRAS inhibitor program to strengthen its early-stage oncology pipeline.
02/07 07:35 EST - InvestorPlace
3 Biotech Stocks to Buy on the Dip: February 2024
Biotech investing is not for impatient investors. So why is it attractive to some investors?
3 Biotech Stocks to Buy on the Dip: February 2024
Biotech investing is not for impatient investors. So why is it attractive to some investors?